Ex vivo expansion of apheresis‐derived peripheral blood hematopoietic progenitors

Because the administration of hematopoietic growth factors and the use of stem cell support often fails to alleviate the neutropenic phase induced by cytotoxic drugs, several investigators have attempted to expand ex vivo hematopoietic progenitors for clinical use. These attempts have clearly shown that the cultured cells are functional and can be safely administered to patients, but that the in vivo performance is disappointing and the concept as a whole is not yet clinically useful. The major reasons for these unsuccessful attempts are thought to be cumbersome cell fractionation techniques, contamination, prolonged incubation, and the use of less than ideal cytokine combinations. In response, we have developed a simple procedure for ex vivo expansion of myeloid progenitor cells. In this assay, unfractionated mononuclear cells from apheresis donors are incubated in nonpyrogenic plastic bags for 7 days in the presence of culture medium either containing fetal calf serum or human plasma, granulocyte colony‐stimulating factor, and stem cell factor. We have demonstrated that under these conditions the number of colony‐forming units (CFU) granulocyte‐macrophage (CFU‐GM) and of CFU‐granulocyte‐macrophage‐erythroid‐megakaryocyte (CFU‐GEMM) increased 7‐ and 9‐fold, respectively, by day 7 and the number of burst‐forming units‐erythroid (BFU‐E) increased 2.7‐fold by day 5 of culture. Significant increases in the numbers of cells expressing CD34+, CD34+/CD38+, CD34+/CD33+, CD34+/CD15+, and CD34+/CD90+ and significant declines in the numbers of cells expressing CD34+/CD38‐ and CD19 surface antigens were also observed. The relative numbers of cells expressing T‐cell markers and CD56 surface antigen did not change. By using different concentrations of various hematopoietic growth factor combinations, we can increase the number of mature and immature cells of different hematopoietic lineages. J. Clin. Apheresis 17:7–16, 2002. © 2002 Wiley‐Liss, Inc.

[1]  E. Ball.  Editorial: Ex Vivo Purging and Cell Expansion , 1999 .

[2]  J. Reiffers,et al.  Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells , 1999, The Lancet.

[3]  M. Gough,et al.  Engraftment of Primates with G‐CSF Mobilized Peripheral Blood CD34+ Progenitor Cells Expanded in G‐CSF, SCF and MGDF Decreases the Duration and Severity of Neutropenia , 1999, Stem cells.

[4]  Lesley J. Murray,et al.  CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo. , 1999, Experimental hematology.

[5]  D. Slamon,et al.  Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media. , 1998, Journal of hematotherapy.

[6]  S. Williams,et al.  Clinical applications of ex vivo cultured CD34+ cells and myeloid progenitors. , 1998, Cytokines, cellular & molecular therapy.

[7]  J. Tisdale,et al.  Ex vivo expansion of genetically marked rhesus peripheral blood progenitor cells results in diminished long-term repopulating ability. , 1998, Blood.

[8]  S. Jacobsen,et al.  Ability of early acting cytokines to directly promote survival and suppress apoptosis of human primitive CD34+CD38- bone marrow cells with multilineage potential at the single-cell level: key role of thrombopoietin. , 1997, Blood.

[9]  J. Dick,et al.  Quantitative Analysis Reveals Expansion of Human Hematopoietic Repopulating Cells After Short-term Ex Vivo Culture , 1997, The Journal of experimental medicine.

[10]  D. Williams,et al.  Neutrophil maturation of CD34+ cells from peripheral blood and bone marrow in serum-free culture medium with PIXY321 and granulocyte-colony stimulating factor (G-CSF). , 1997, Journal of hematotherapy.

[11]  S. Jacobsen,et al.  Thrombopoietin directly and potently stimulates multilineage growth and progenitor cell expansion from primitive (CD34+ CD38-) human bone marrow progenitor cells: distinct and key interactions with the ligands for c-kit and flt3, and inhibitory effects of TGF-beta and TNF-alpha. , 1997, Journal of immunology.

[12]  I. Mcniece,et al.  Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. , 1997, Journal of hematotherapy.

[13]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[14]  D. Dunlop,et al.  CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Sutherland,et al.  The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. , 1996, Journal of hematotherapy.

[16]  T. Soma,et al.  Maintenance of murine long-term repopulating stem cells in ex vivo culture is affected by modulation of transforming growth factor-beta but not macrophage inflammatory protein-1 alpha activities. , 1996, Blood.

[17]  J G Bender,et al.  Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. , 1996, Blood.

[18]  A. Hagenbeek,et al.  Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. , 1995, The New England journal of medicine.

[19]  X. Thomas,et al.  Expression of N-CAM (CD56) on acute leukemia cells: relationship with disease characteristics and outcome. , 1995, Leukemia & lymphoma.

[20]  L. Seymour,et al.  High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  J. Jansen,et al.  Maturation of mobilized peripheral blood progenitor cells: preclinical and phase I clinical studies. , 1995, Journal of hematotherapy.

[22]  R. Mick,et al.  Source of stem cells impacts on hematopoietic recovery after high-dose chemotherapy. , 1995, Bone marrow transplantation.

[23]  P. Quesenberry,et al.  Murine marrow cells expanded in culture with IL-3, IL-6, IL-11, and SCF acquire an engraftment defect in normal hosts. , 1995, Experimental hematology.

[24]  R. Storb,et al.  Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor , 1995 .

[25]  N. Schmitz,et al.  Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor) , 1995, Blood.

[26]  H. Ramshaw,et al.  Engraftment of bone marrow cells into normal unprepared hosts: effects of 5-fluorouracil and cell cycle status. , 1995, Blood.

[27]  P. Lansdorp,et al.  Selection of retrovirally transduced hematopoietic cells using CD24 as a marker of gene transfer. , 1994, Blood.

[28]  G. Baldwin,et al.  Production of functional myeloid cells from CD34‐selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system , 1994, Stem cells.

[29]  L. Lum,et al.  Expansion of neutrophil precursors and progenitors in suspension cultures of CD34+ cells enriched from human bone marrow. , 1993, Experimental hematology.

[30]  A. Nagler,et al.  Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. , 1992, Blood.

[31]  L. To,et al.  Ex vivo expansion and maturation of peripheral blood CD34+ cells into the myeloid lineage. , 1992, Blood.

[32]  R. M. Fox,et al.  Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy , 1992, The Lancet.

[33]  R. Frenck,et al.  Studies of the Function and Structure of In Vitro Propagated Human Granulocytes , 1991, Pediatric Research.

[34]  Timothy A. Springer,et al.  Adhesion receptors of the immune system , 1990, Nature.

[35]  R. Bast,et al.  Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. , 1988, The New England journal of medicine.

[36]  G. Marit,et al.  Successful autologous transplantation with peripheral blood hemopoietic cells in a patient with acute leukemia. , 1986, Experimental hematology.

[37]  B. Dörken,et al.  Autologous transplantation of blood-derived hemopoietic stem cells after myeloablative therapy in a patient with Burkitt's lymphoma. , 1986, Blood.

[38]  A. Fauser,et al.  Granuloerythropoietic colonies in human bone marrow, peripheral blood, and cord blood , 1978 .

[39]  Y. S. Sathe,et al.  Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. , 1966, Annals of internal medicine.